Eli Lilly and Company (LLY)vsTscan Therapeutics Inc (TCRX)
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
TCRX
Tscan Therapeutics Inc
$1.15
-8.73%
HEALTHCARE · Cap: $75.73M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 631174% more annual revenue ($65.18B vs $10.32M). LLY leads profitability with a 31.7% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
TCRX
Hold40
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
-23.1%
Fair Value
$0.79
Current Price
$1.15
$0.36 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Reasonable price relative to book value
Revenue surging 286.0% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -71.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : TCRX
The strongest argument for TCRX centers on Price/Book, Revenue Growth. Revenue growth of 286.0% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : TCRX
The primary concerns for TCRX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
LLY profiles as a growth stock while TCRX is a hypergrowth play — different risk/reward profiles.
TCRX carries more volatility with a beta of 1.01 — expect wider price swings.
TCRX is growing revenue faster at 286.0% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 40/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Tscan Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tscan Therapeutics Inc (TCRX) is a clinical-stage biotechnology company committed to revolutionizing cancer treatment through its advanced T cell receptor (TCR) discovery platform, which targets specific cancer antigens for precision immunotherapy solutions. The firm’s innovative approach aims to translate cutting-edge scientific research into effective TCR-based therapeutics, enhancing treatment options for a variety of malignancies. With a robust pipeline and a solid intellectual property portfolio, Tscan Therapeutics is strategically positioned to become a key player in the fast-growing sector of T cell-based cancer therapies, addressing significant unmet medical needs and improving patient outcomes.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?